ArticleJournal of clinical laboratory analysis2021
Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.
Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.British journal of cancer · 2026Article
- The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Tumor antigen-associated autoantibodies: generation mechanisms, roles in tumorigenesis and progression, and clinical application prospects.Frontiers in immunology · 2026Review
- Multiple Tumor-related autoantibodies test enhances CT-based deep learning performance in diagnosing lung cancer with diameters < 70 mm: a prospective study in China.BMC pulmonary medicine · 2025Article
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.Frontiers in immunology · 2025Article
- Diagnostic value of multi-tumor-associated autoantibody expression in esophageal squamous cell carcinoma and correlation of clinical features.Frontiers in immunology · 2024Article
- Improvement in the performance of an autoantibody panel in combination with heat shock protein 90a for the detection of early‑stage lung cancer.Experimental and therapeutic medicine · 2023Article
- Efficacy of autoantibodies combined with tumor markers in the detection of lung cancer.Journal of clinical laboratory analysis · 2022Article
- Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.Journal of clinical laboratory analysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe purpose of this study was to analyze the levels of tumor-associated autoantibodies (TAAbs) in lung diseases and determine their diagnostic efficiency in early-stage non-small cell lung cancer (NSCLC).
methodsWe retrospectively analyzed the levels of 7-TAAbs in 177 newly diagnosed early-stage NSCLC patients, 202 patients with lung benign diseases and 137 healthy cases. The levels of a panel of 7-TAAbs, including p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5, were measured by ELISA.
resultsThe serum levels of p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, and GBU4-5 were not statistically different among NSCLC, benign and healthy groups (p > 0.05). The area under the curve (AUC) of 7-TAAbs was all lower than 0.70. The sensitivity of combined detection was the highest (23.73%), while the specificity was the lowest (88.79%). The positive rates of PGP9.5, SOX2, and combined detection were significantly different among the three groups (p < 0.05). Among them, PGP9.5 and combined detection were significantly different between the NSCLC and benign groups (p < 0.05), PGP9.5, SOX2 and combined detection were significantly different between the NSCLC and healthy groups (p < 0.05).
conclusionsThe diagnostic efficiency of 7-TAAbs in early-stage NSCLC was not high, so it cannot be used alone as a screening method for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.